Validation of Accept, a New Generic Measure to Assess How Patients with Chronic Diseases Balance Between the Advantages and Disadvantages of Following the Recommended Treatment Regimen in Real-life

Abstract

A335 were asked to complete Accept and MMAS-4 questionnaires at Month 1, 3 and 6 after having given their informed consent. The structure was explored through PCA, and confirmed with multi-trait analysis. Internal consistency reliability of dimensions was assessed through Cronbach's alpha. Scale-scale correlations were calculated. Results: After reduction, Accept was made of 25 items organised in 1 overall Acceptance score and 6 domain-specific scores (efficacy, tolerance, convenience, constraints, treatment duration, multiple medication). Cronbach's alpha was 0,85 for overall Acceptance score, which met convergent and divergent validity criteria (both 100%). The domain-specific scores showed satisfactory to good results (Cronbach's alpha ranging from 0,67-0,87, convegrent validity ranging from 63% to 100%, and divergent validity ranging from 33%-100%). Scale-scale correlations ranged from 0.02 to 0.58, confirming the multi-dimensional nature of the questionnaire. The good properties of Accept were stable over time. ConClusions: Accept is a brief, comprehensive, generic questionnaire focused on Acceptance. Initial validation in a population of patients with a wide range of long-term treatment showed promising results and confirmed the position of Acceptance. Further, disease-specific, large prospective study are needed to assess the ability of Accept to predict persistence to treatment.

User‐Centered Design to Develop Automated Short Message Service Messaging for Patient Support of Rheumatic Heart Disease Secondary Antibiotic Prophylaxis

“…Potential participants were excluded if they were aged <13 years, did not have access to a telephone capable of sending and receiving an SMS, or were not prescribed SAP. Participants completed the Chronic Treatment Acceptance (ACCEPT) questionnaire 15 , 16 , 17 , 18 at enrollment and 2 months after the SMS intervention deployment to assess their acceptance of SAP. ACCEPT is a 25‐item questionnaire to evaluate patients' long‐term treatment acceptance.…”

Assessing patients’ acceptance of their medication to reveal unmet needs: results from a large multi-diseases study using a patient online community

“…The ACCEPT© questionnaire is a generic patient-reported outcome questionnaire specifically developed to assess patients’ acceptance of long-term medications. Its development and its psychometric validation included a literature review, pharmacist and patient interviews, and a specific validation study conducted with 189 patients recruited through pharmacists [ 12 , 13 ]. The ACCEPT© questionnaire comprises seven independent dimensions: one on general acceptance (Acceptance/General) and six treatment-attribute specific, covering all specific attributes of drug: Acceptance/Medication Inconvenience, Acceptance/Long-term Treatment, Acceptance/Regimen Constraints, Acceptance/Numerous Medications, Acceptance/Side effects, and Acceptance/Effectiveness (Table 1 ).…”

“…Thus, measuring patient acceptance of their medication should help to better understand and predict patients’ behavior toward treatment and identify unmet needs. The generic ACCEptance by the Patients of their Treatment (ACCEPT©) questionnaire has been developed to measure how patients perceive advantages and disadvantages of their long-term medications [ 12 , 13 ].…”

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence

“…Patient satisfaction, convenience and adherence were evaluated in phase III (EAGER) and phase IV (2403, FREE, FR01, and GB01) studies using different questionnaires such as the modified-treatment satisfaction questionnaire for medication (TSQM), 54 , 55 ACCEPTance, 56 the revised cystic fibrosis questionnaire (CFQ-R), 57 the Italian CFQ (ITA-CFq), and the Morisky scale. 58 EAGER, 2403, FREE, and GB01 studies utilized the TSQM questionnaire for evaluating patients reported outcomes (effectiveness, satisfaction, convenience, and side effects).…”